Aditxt Prices $4.2M Private Placement
Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a company dedicated to discovering, developing, and deploying promising health innovations, today announced that it has entered into securities purchase agreements
Aditxt, Inc. Merger With Evofem Biosciences Falls Through
Aditxt Said On April 26 Received Notice From Evofem That Evofem Was Exercising Its Right To Terminate Merger Agreement As Result Of Co's Failure To Provide Initial Parent Equity Investment
Aditxt Said On April 26 Received Notice From Evofem That Evofem Was Exercising Its Right To Terminate Merger Agreement As Result Of Co's Failure To Provide Initial Parent Equity Investment
Aditxt, Inc. Announces Strategic Acquisition of Appili Therapeutics
Why Aditxt Stock Is Volatile Today
Aditxt, Inc. (NASDAQ:ADTX) shares are volatile Tuesday after the company announced it will acquire Appili Therapeutics.The Details:Aditxt's wholly owned subsidiary, Adivir, Inc. will acquire all issue
Decoding The Spike: Understanding Aditxt (ADTX) Shares' Significant Increase
Aditxt, Inc. (NASDAQ: ADTX) is observing a notable surge of 25.47% in its shares during the current session, escalating to a price of $3.99. This significant increase in ADTX shares within the US market can be directly attributed to the disclosure of an acquisition agreement. Aditxt (ADTX) officially stated today that it has reached a ...
Canopy Growth, Exact Sciences, Stereotaxis Among Healthcare Movers
Aditxt Shares Resume Trade
Aditxt Shares Resume Trade
Adixit Shares Halted On Circuit Breaker To The Downside, Stock Now Up 45.9%
Adixit Shares Halted On Circuit Breaker To The Downside, Stock Now Up 45.9%
Aditxt to Buy Biopharmaceutical Company Appili Therapeutics for Undisclosed Amount
By Chris Wack Aditxt said it will buy Appili Therapeutics for an undisclosed amount through a court-approved plan of arrangement under the Canada Business Corporations Act. Aditxt said Tuesday that
Press Release: Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)
Assets include the FDA-approved LIKMEZ(TM), the ATI-1701 tularemia vaccine defense program that has been awarded a USD $14 million non-dilutive award from the DoD, and the ATI-1801 topical formulation
Aditxt, Through Adivir Subsidiary, To Acquire All Issued And Outstanding Class A Common Shares Of Appili; Appili Shareholders To Receive 0.002745004 Shares Of Aditxt And $0.0467 For Each Appili Share Held, Representing Total Consideration Of ~$0.0561
Under the terms of the Arrangement Agreement, shareholders of Appili (the "Appili Shareholders") will receive (i) 0.002745004 of a share of common stock (each whole share, an "Aditxt Share") of Aditxt
Appili Therapeutics Signs Definitive Agreement to Be Acquired by Aditxt, Inc.
Evofem Biosciences 4Q Loss/Shr 44c >EVFM
Evofem Biosciences 4Q Loss/Shr 44c >EVFM
Evofem Reports $18.2 Million of Phexxi Net Product Sales in 2023
The company behind Phexxi (lactic acid, citric acid, and potassium bitartrate) vaginal gel, women's health innovator Evofem Biosciences, Inc....
Evofem Negotiates Improved Rebate for Hormone-Free "In the Moment" Contraceptive PHEXXI With Medi-Cal
Commercial-stage women's health innovator Evofem Biosciences, Inc. (OTCQB: EVFMD) today announced that it has successfully renegotiated the rebate...
For Women Using GLP-1 Receptor Agonists Who Take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel Is a Logical Solution to Help Prevent Unintended Pregnancy
Use of GLP-1 receptor agonists, or GLP-1s, is skyrocketing in the United States, with more than nine million prescriptions for Ozempic, Wegovy,...
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersNKGen Biotech (NASDAQ:NKGN) shares increased by 69.4% to $1.46 during Wednesday's pre-market session. The market value of their outstanding shares is at $31.9 million. Creative Medical Tech (NA
Aditxt Secures Dawson James for M&A Advisory Role
No Data